SanegeneBio
Financing Round
- Series B
Round Led or Co-led By SymBiosis
SanegeneBio is a fully-integrated biotechnology company focused on developing RNAi-based therapeutics. Founded in 2021 and led by a team of RNAi veterans, the company has R&D operations in Boston, Shanghai and Suzhou. SanegeneBio has initiated clinical trials for multiple experimental medicines and is committed to developing potential best-in-class and first-in-class therapeutics which leverage its LEAD™ tissue-selective RNAi delivery technology. The company’s fast-growing pipeline includes experimental medicines for autoimmune nephropathies, obesity, and cardiometabolic indications.
View Website
Modality
- Genetic Medicine
Indications
- Circulatory & Metabolic Disease
- Immunology & Inflammation
Development Status
- Phase 1